Carlo Genova

6.2k total citations · 1 hit paper
144 papers, 2.7k citations indexed

About

Carlo Genova is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Carlo Genova has authored 144 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Oncology, 86 papers in Pulmonary and Respiratory Medicine and 26 papers in Molecular Biology. Recurrent topics in Carlo Genova's work include Lung Cancer Treatments and Mutations (69 papers), Cancer Immunotherapy and Biomarkers (47 papers) and Lung Cancer Research Studies (36 papers). Carlo Genova is often cited by papers focused on Lung Cancer Treatments and Mutations (69 papers), Cancer Immunotherapy and Biomarkers (47 papers) and Lung Cancer Research Studies (36 papers). Carlo Genova collaborates with scholars based in Italy, United States and United Kingdom. Carlo Genova's co-authors include Francesco Grossi, Maria Giovanna Dal Bello, Simona Coco, Erika Rijavec, Giovanni Rossi, Angela Alama, Federica Biello, Giulia Barletta, Marco Tagliamento and Biagio Ricciuti and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Carlo Genova

138 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade

2022 154 citations Carlo Genova, Chiara Dellepiane et al. profile →

Peers

Carlo Genova

ONCOL

PRM

IMMUN

Yoichi Naito Japan

Dickran Kazandjian United States

Maria Giovanna Dal Bello Italy

Kevin Punie Belgium

Antonio Passaro Italy

Haiying Cheng United States

Alex Friedlaender Switzerland

Anna Spreafico Canada

Jifang Gong China

Christina S. Baik United States

Yoichi Naito Japan

Carlo Genova

1.7k ×1.0

ONCOL

1.1k ×0.9

PRM

623 ×0.9

428 ×0.7

355 ×0.7

IMMUN

Citations per year, relative to Carlo Genova Carlo Genova (= 1×) peers Yoichi Naito

Countries citing papers authored by Carlo Genova

Since Specialization

Citations

This map shows the geographic impact of Carlo Genova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlo Genova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlo Genova more than expected).

Fields of papers citing papers by Carlo Genova

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlo Genova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlo Genova. The network helps show where Carlo Genova may publish in the future.

Co-authorship network of co-authors of Carlo Genova

This figure shows the co-authorship network connecting the top 25 collaborators of Carlo Genova. A scholar is included among the top collaborators of Carlo Genova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlo Genova. Carlo Genova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ballabio, M., Lorenzo Ferrando, Giovanni Talerico, et al.. (2025). Influence of medical educational background on the diagnostic quality of ChatGPT‐4 responses in internal medicine: A pilot study. European Journal of Clinical Investigation. 55(11). e70113–e70113. 1 indexed citations

Rossi, Giovanni, Marco Tagliamento, Enrica T. Tanda, et al.. (2025). Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses. ESMO Open. 10(9). 105759–105759.

Hysa, Elvis, Andrea Casabella, Emanuele Gotelli, et al.. (2024). Clinical outcomes in cancer patients with immune checkpoint inhibitor-induced arthritis treated with methotrexate: a retrospective longitudinal monocentric pilot study. Clinical and Experimental Rheumatology. 43(5). 867–873. 1 indexed citations

Hysa, Elvis, Andrea Casabella, Emanuele Gotelli, et al.. (2024). Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: A systematic literature review highlighting differences from the idiopathic forms. Autoimmunity Reviews. 23(7-8). 103589–103589. 15 indexed citations

Barisione, Emanuela, et al.. (2024). Rapid On-Site Evaluation Performed by an Interventional Pulmonologist: A Single-Center Experience. Journal of Personalized Medicine. 14(7). 764–764.

Zullo, Lodovica, Mihaela Aldea, V. Fontana, et al.. (2023). 1456P Exploring biological and molecular factors as outcome predictors for pembrolizumab (Pem) or pembrolizumab-chemotherapy (Pem-CT) in advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 34. S827–S828. 1 indexed citations

Tagliamento, Marco, Massimo Di Maïo, Jordi Remón, et al.. (2023). Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma. Journal of Thoracic Oncology. 19(1). 166–172. 8 indexed citations

Zullo, Lodovica, Filippo Gustavo Dall’Olio, Giovanni Rossi, et al.. (2023). Molecular and Genetic Advances in Small Cell Lung Cancer Landscape: From Homogeneity to Diversity. International Journal of Molecular Sciences. 25(1). 224–224. 3 indexed citations

Rijavec, Erika, Federica Biello, Alice Indini, Francesco Grossi, & Carlo Genova. (2022). Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib. SHILAP Revista de lepidopterología. 7 indexed citations

10.

Rossi, Giovanni, Alessandro Fedeli, Lodovica Zullo, et al.. (2022). Exploring Response to Immunotherapy in Non-Small Cell Lung Cancer Using Delta-Radiomics. Cancers. 14(2). 350–350. 34 indexed citations

11.

Zullo, Lodovica, Giovanni Rossi, Simona Coco, et al.. (2022). Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives. Expert Opinion on Biological Therapy. 22(10). 1259–1273. 17 indexed citations

12.

Rebuzzi, Sara Elena, Lodovica Zullo, Giovanni Rossi, et al.. (2021). Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. 22(5). 2625–2625. 40 indexed citations

13.

Rossi, Giovanni, Lodovica Zullo, Luigi Cerbone, et al.. (2020). ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium. Expert Opinion on Pharmacotherapy. 21(6). 679–686. 2 indexed citations

14.

Rossi, Giovanni, Alessandro Russo, Marco Tagliamento, et al.. (2020). Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. Cancers. 12(5). 1125–1125. 48 indexed citations

15.

Rossi, Giovanni, Alessandro Fedeli, Gianluca Ficarra, et al.. (2020). Radiomic Detection of EGFR Mutations in NSCLC. Cancer Research. 81(3). 724–731. 78 indexed citations

16.

Alama, Angela, Simona Coco, Carlo Genova, et al.. (2019). Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab. Journal of Clinical Medicine. 8(7). 1011–1011. 45 indexed citations

17.

Bonaventura, Aldo, Francesco Grossi, Federico Carbone, et al.. (2019). Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study. Cancer Immunology Immunotherapy. 68(8). 1351–1358. 28 indexed citations

18.

Rossi, Giovanni, Angela Alama, Carlo Genova, et al.. (2018). The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer. Expert Opinion on Pharmacotherapy. 19(17). 1969–1976. 17 indexed citations

19.

Coco, Simona, Angela Alama, Irene Vanni, et al.. (2017). Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy. International Journal of Molecular Sciences. 18(5). 1035–1035. 37 indexed citations

20.

Alama, Angela, Anna Truini, Simona Coco, Carlo Genova, & Francesco Grossi. (2014). Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer. Drug Discovery Today. 19(10). 1671–1676. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact